The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MDS 2021 | Immunological impact of TP53 in MDS
Shahram Kordasti
• 27 Jan 2021
Shahram Kordasti, MD, PhD, King’s College London, London, UK, discusses the immunological effects of TP53 mutations in myelodysplastic syndromes (MDS) and how these impact prognosis. This interview took place during the 2021 European School of Hematology (ESH) 7th Translational Research E-Conference on Myelodysplastic Syndromes.
